Zoladex and Flutamide Versus Orchiectomy in the Treatment of Advanced Prostatic Cancer

A total of 591 patients with advanced prostatic cancer have been randomized to either orchiectomy or treatment with zoladex 3.6 mg as a depot preparation combined with flutamide 250 mg tid in two European studies, EORTC protocol 30853 and DAPROCA 86. Identical design and comparable patient characteristics in the two studies have allowed combined analysis. A small but statistically significant difference in time to objective progression or death from prostatic cancer was found in favor of the combination treatment. However, time from objective progression to death was longer in the group initially allocated to orchiectomy. Thus, no difference between treatment groups in overall survival was found. As a conclusion, the combined androgen blockade was not superior to orchiectomy in the treatment of patients with advanced prostatic cancer.

[1]  L. Denis,et al.  Combined castration and androgen blockade therapy in prostate cancer. Conclusions. , 1990, Cancer.

[2]  C. Rose,et al.  A Phase III Trial of Zoladex and Flutamide Versus Orchiectomy in the Treatment of Patients With Advanced Carcinoma of the Prostate , 1990, Cancer.

[3]  R. Sylvester,et al.  Comparability of EORTC and DAPROCA Studies in Advanced Prostatic Cancer , 1990, Cancer.

[4]  Conclusions , 1989 .

[5]  P. Goodman,et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.

[6]  R. Sylvester,et al.  Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials. , 1989, The Journal of urology.

[7]  C. Pelizzari,et al.  Basic and clinical radiation physics. , 1988, American Journal of Clinical Oncology.

[8]  J. Geller,et al.  Advantages of total androgen blockade in the treatment of advanced prostate cancer. , 1988, Seminars in oncology.

[9]  J. Trachtenberg,et al.  Total Androgen Blockade for Metastatic Cancer of the Prostate , 1987, American Journal of Clinical Oncology.

[10]  M. Robinson.  Complete androgen blockade: the EORTC experience comparing orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose stilboestrol in the treatment of metastatic carcinoma of the prostate. , 1987, Progress in clinical and biological research.

[11]  R. Priore,et al.  Prognostic factors in patients with advanced stage prostate cancer. , 1985, Cancer research.

[12]  F. Labrie,et al.  Complete androgen blockade for the treatment of prostate cancer. , 1985, Important advances in oncology.

[13]  Leuprolide versus diethylstilbestrol for metastatic prostate cancer. , 1984, The New England journal of medicine.

[14]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .